Faculty offer expert insights into emerging data on BTK inhibitor resistance in CLL, referencing earlier findings that indicate the potential existence of mutations before BTK inhibitor exposure and the process of clonal selection.
Richard Furman, MD, outlines his strategy for addressing BTK inhibitor intolerance in CLL patients, underscoring the significance of BTK inhibitors in CLL treatment and advocating for transitioning to an alternative BTK inhibitor rather than completely discontinuing the class in cases of drug intolerance.
Chaitra S. Ujjani, MD examines extended follow-up data from the ALPINE trial, emphasizing noteworthy findings from the sensitivity and safety analyses recently presented at ASH 2023.